POCUS-Guided Diuresis for Decompensated Heart Failure

NARecruitingINTERVENTIONAL
Enrollment

588

Participants

Timeline

Start Date

June 29, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Heart Decompensation, AcuteAcute Kidney Injuries
Interventions
OTHER

Furosemide (Standard Diuretic) Treatment

Participants in this group will receive intravenous furosemide as part of their routine care, based on clinical assessments including symptoms, physical examination. Daily POCUS imaging will be performed for research purposes; however, the findings will not be shared with the treating clinical team. Fluid management decisions and discharge planning will follow usual care protocols, without additional imaging-based guidance.

OTHER

POCUS-Assessed Diuretic Management

POCUS will be used to provide objective, non-invasive assessments of fluid status by measuring right internal jugular vein (RIJV) cross-sectional area (CSA) and calculating the Distensibility Index (DI). This information will be shared with the treating clinical team as an additional tool for fluid management. However, all final decisions regarding diuretic therapy will be made at the discretion of the treating physicians.

Trial Locations (3)

15213

NOT_YET_RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

RECRUITING

UPMC Presbyterian, Pittsburgh

15232

RECRUITING

UPMC Shadyside, Pittsburgh

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

University of Pittsburgh

OTHER

NCT06921603 - POCUS-Guided Diuresis for Decompensated Heart Failure | Biotech Hunter | Biotech Hunter